Vertex (VRTX) Begins Rolling NDA Filing for Acute Pain Drug
ZacksVertex (VRTX) begins rolling NDA submission for its investigational non-opioid candidate, suzetrigine, for acute pain management. The submission is expected to be completed in second-quarter 2024.